



October 29, 2008

---

### **Society Publishes Two New Clinical Practice Guidelines**

This month's mailing of *Endocrine News* included the Society's latest clinical practice guideline, *Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism*. The guideline was developed by a task force of content experts chaired by John W. Funder, M.D., Ph.D. The guideline was approved by The Endocrine Society's Council in January 2008 and published in the September issue of the *Journal of Clinical Endocrinology and Metabolism*. Some of the issues addressed in the guideline are the definition and clinical significance of primary aldosteronism, subtype classification, and treatment.

The Society's next guideline, *Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk*, will be mailed with the November issue of *Endocrine News*. Developed by a task force led by James L. Rosenzweig, M.D., the guideline examines the definition and diagnosis of metabolic syndrome, the absolute risk assessment, and the treatments to prevent atherosclerotic cardiovascular disease and type 2 diabetes.

All published Society clinical practice guidelines are available at <http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm>. The guideline on metabolic syndrome will be available in mid-November.

The Society has nine other guidelines nearing completion and coming soon. Please contact the Society's Government & Public Affairs department at [govt-prof@endo-society.org](mailto:govt-prof@endo-society.org) for more information.

### **CDMRP Breast and Ovarian Cancer Research Funding Increase**

The Fiscal Year 2009 Defense Appropriation Act (Public Law 110-329) provides research funding for the following endocrine-related programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP):

- Breast Cancer Research Program \$150 Million (9% increase over FY08)
- Prostate Cancer Research Program \$80 Million (no change from FY08)
- Ovarian Cancer Research Program \$20 Million (double FY08 levels)
- Peer Reviewed Medical Research Program \$50 Million (PRMRP; no change from FY08)

Osteoporosis and related bone disease is one topic among many included in the PRMRP.

The DOD has not issued Program Announcements yet, but has stated it will do so in fall 2008 and early 2009, including detailed descriptions of funding mechanisms, evaluation criteria, submission requirements, and deadlines. Details about the program, and Program

Announcements as available, may be found at the CDMRP website at <http://cdmrp.army.mil>. Program Announcements will also be posted at [www.grants.gov](http://www.grants.gov).

### **Society Helps Establish Clearer Coding for Secondary Diabetes**

As of October 1, 2008, new codes for classifying secondary diabetes have been added to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding system. Previously, secondary diabetes was coded using ICD-9-CM code 251.8, a single code that was not specific to secondary diabetes but was used to categorize “other specified disorders of pancreatic internal secretion.” The new codes 249.00-249.91 allow for more specificity in identifying complications and level of control.

The Centers for Disease Control and Prevention’s National Center for Health Statistics (NCHS), which creates and revises codes under the ICD system, approached The Endocrine Society in 2007 for comments on whether secondary diabetes required its own diagnosis code. The Society provided input indicating its support for new secondary diabetes diagnosis codes 249.00-249.91, specifying that the code should allow physicians to indicate level of control. The fourth digit of the new code provides for categorization based on type of complication and, in line with the Society’s recommendation, the fifth digit differentiates between controlled and uncontrolled cases. Providers must now use the new codes for secondary diabetes; failure to do so will cause instant rejections and unpaid claims.

For more information on ICD-9-CM coding for secondary diabetes, please see the NCHS webpage at [www.cdc.gov/nchs/icd9.htm](http://www.cdc.gov/nchs/icd9.htm).

### **New E-Prescribing Guide Available for Clinicians**

The American Medical Association, American College of Physicians, American Academy of Family Physicians, and the Medical Group Management Association have developed a new report, *A Clinician’s Guide to Electronic Prescribing*. The guide provides information for clinicians interested in learning more about electronic prescribing (e-prescribing), including specific information for office-based clinicians ready to begin implementation of e-prescribing in their practice.

E-prescribing can be conducted using a stand-alone program or can be integrated into an electronic medical record. In 2009, the Medicare program will begin a new e-prescribing initiative that will provide financial incentives for clinicians who choose to e-prescribe. Qualifications and details on the Medicare initiative, as well as details on the basics of e-prescribing and how to choose and implement an e-prescribing program, are included in *A Clinician’s Guide to Electronic Prescribing*, which can be found at <http://www.ama-assn.org/ama1/pub/upload/mm/472/electronic-e-prescribing.pdf>.

### **Endocrine Society Member Phyllis Wise Elected to the Institute of Medicine**

Phyllis Wise, Ph.D., provost and professor of physiology, biophysics, obstetrics, and gynecology at the University of Washington in Seattle, has become the latest member of The Endocrine Society to be elected to the Institute of Medicine (IOM). Dr. Wise has been a member of the Society for 32 years, serving in several capacities including on the Awards Committee, Nominating Committee, Editorial Board, and Program Committee.

Membership in the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievements and commitment to service. With their election, members make a commitment to give volunteer time to Institute committees that engage in a broad range of studies of health issues.

For questions regarding articles listed in *Endocrine Insider* or information on advocacy and policy activities within The Endocrine Society, contact the Government & Public Affairs department:

Janet B. Kreizman, Senior Director  
301-941-0252  
[Jkreizman@endo-society.org](mailto:Jkreizman@endo-society.org)

Charles E. Blue, Director, Media Relations  
301-941-0240  
[Cblue@endo-society.org](mailto:Cblue@endo-society.org)

Stephanie Kutler, Assoc. Director  
301-941-0254  
[Skutler@endo-society.org](mailto:Skutler@endo-society.org)

Loretta L. Doan, PhD, Assoc. Dir., Science Policy  
301-941-0258  
[Ldoan@endo-society.org](mailto:Ldoan@endo-society.org)

Lisa Marlow, Manager  
240-482-1392  
[Lmarlow@endo-society.org](mailto:Lmarlow@endo-society.org)

Holly Whelan, Manager, Health Policy  
301-951-2613  
[Hwhelan@endo-society.org](mailto:Hwhelan@endo-society.org)

Aaron Lohr, Manager, Media Relations  
240-482-1380  
[Alohr@endo-society.org](mailto:Alohr@endo-society.org)

Stacey Trunnell, Administrative Assistant  
240-482-1389  
[Strunnell@endo-society.org](mailto:Strunnell@endo-society.org)